Article
Systematic review of the mutations in the active antigenic site Ø of the prefusion F protein of the Respiratory Syncytial Virus (RSV) following the implementation of monoclonal antibody prophylaxis.
Vaccine - 3 Oct 2026
Berikopoulou Maria M, Tatsi Elizabeth-Barbara, Siahanidou Tania, Michos Athanasios
Abstract excerpt
BACKGROUND: Monoclonal antibody (mAb) nirsevimab, which targets the antigenic site Ø of the prefusion F protein (pre-F) of RSV, was introduced for RSV prophylaxis in several countries. METHODS: A systematic search was conducted between January 1, 2022, and July 31, 2026 for studies analyzing substitutions within the epitope of pre-F RSV protein, which is the target of nirsevimab, after the implementation of the...
Read the complete abstract on PubMedTopics
- Humans
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antiviral Agents
- Drug Resistance, Viral